周剂量依立替康联合卡培他滨二线治疗晚期胃癌:附21例报道  

Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer:an analysis of 21 cases

作　　者：刘瑛[1] 康马飞[1] 骆梅青[1] 董翠梅[1] 

机构地区：[1]桂林医学院附属医院肿瘤内科,广西桂林541001

出　　处：《南方医科大学学报》2010年第11期2575-2576,2580,共3页Journal of Southern Medical University

摘　　要：目的观察周剂量依立替康联合卡培他滨二线治疗晚期胃癌的疗效和不良反应。方法收集2008年6月～2009年2月我科以周剂量依立替康联合卡培他滨治疗一线化疗失败的晚期胃癌患者21例,第1、8天给予依立替康85mg/m2,静脉滴注90min;第1～14天给予卡培他滨1000mg/m2,口服,2次/d,21d为1个周期。每例患者治疗至少2个周期,2个周期化疗完成后4星期评价疗效。结果在可评价疗效的21例患者中,完全缓解(CR)0例,部分缓解(PR)5例(23.8%),疾病稳定(SD)6例(28.6%),疾病进展(PD)10例(47.6%),总有效率(CR+PR)23.8%,临床获益者(CR+PR+SD)共11例(52.4%)。平均肿瘤进展时间为(3.61±0.97)个月。不良反应主要为骨髓抑制、恶心呕吐和腹泻。结论周剂量依立替康联合卡培他滨二线治疗晚期胃癌疗效好,不良反应可耐受。Objective To evaluate the efficacy and adverse effects of weekly irinotecan combined with capecitabine as a second-line chemotherapy for treatment of advanced gastric cancer.Methods Twenty-one patients with advanced gastric cancer who had failed first-line therapy received irinotecan on days 1 and 8 plus capecitabine on days 1-14 for a 21-day cycle.Each patient was treated for at least two cycles and evaluated 4 weeks later for the responses.Results Of the 21 patients,none showed complete remission（CR）,5（23.8%） showed partial remission（PR）,6（28.6%） showed stable disease（SD） and 10（47.6%） showed progressive disease（PD）.The overall response rate was 23.8%,and 11 patients（52.4%） benefited（CR＋PR＋SD） from the clinical therapy,with a mean time to tumor progression of 3.61±0.97 months.The main adverse effects of this regimen included myelosuppression,nausea,vomiting and diarrhea.Conclusion The regimen of weekly irinotecan plus capecitabine has a definite effect for treatment of advanced gastric cancer with tolerable toxicity.

关 键 词：晚期胃癌 依立替康 卡培他滨 

分 类 号：R735.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]